Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Next Previous
Search
Trial Profile

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Epizyme

    • Most Recent Events

    • 07 Jun 2022 Results reporting data on updated efficacy, safety, subgroup and translational analyses presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2022 According to an Epizyme media release, data from this study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, during the Hematologic Malignancies Poster Session.
    • 23 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top